Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma

Omar Castaneda-Puglianini,1 Julio C Chavez2 1Virginia Commonwealth University, Massey Cancer Center, Cellular Immunotherapies and Transplant Program, Richmond, VA, USA; 2Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USACorrespondence: Julio C ChavezDepartment of Malignant Hem...

Full description

Bibliographic Details
Main Authors:	Castaneda-Puglianini O, Chavez JC
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-08-01
Series:	Journal of Blood Medicine
Subjects:	car-t neurotoxicity icans encephalopathy
Online Access:	https://www.dovepress.com/assessing-and-management-of-neurotoxicity-after-car-t-therapy-in-diffu-peer-reviewed-fulltext-article-JBM

Similar Items

Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma
by: Semira Sheikh, et al.
Published: (2022-02-01)

Editorial: Novel insights into CAR T-cell associated neurotoxicity
by: Stella Bouziana
Published: (2023-11-01)

Cytokines in CAR T Cell–Associated Neurotoxicity
by: Juliane Gust, et al.
Published: (2020-12-01)

Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome
by: Tim Lakomy, et al.
Published: (2023-02-01)

Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
by: Robert C. Sterner, et al.
Published: (2022-08-01)

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
by: Xinyi Xiao, et al.
Published: (2021-11-01)

Novel pathophysiological insights into CAR-T cell associated neurotoxicity
by: Vassilis Genoud, et al.
Published: (2023-03-01)

CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap
by: Lidia Gatto, et al.
Published: (2023-06-01)

EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study
by: Felix Korell, et al.
Published: (2022-04-01)

A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome
by: Omar H. Butt, et al.
Published: (2023-02-01)

CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?
by: Roser Velasco, et al.
Published: (2023-04-01)

Building safety into CAR-T therapy
by: Daniel T. Peters, et al.
Published: (2023-12-01)

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
by: Zhenguang Wang, et al.
Published: (2018-01-01)

Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
by: Puri Ferreros, et al.
Published: (2022-07-01)

The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions
by: Yanping Li, et al.
Published: (2022-10-01)

It Is in the Eye of the Beholder: Ocular Ultrasound Enhanced Monitoring of Neurotoxicity after CAR-T Cell Therapy
by: Juan Esteban Garcia-Robledo, et al.
Published: (2022-12-01)

Ertapenem-Induced Neurotoxicity: A Literature Review of Clinical Characteristics and Treatment Outcomes
by: Wang C, et al.
Published: (2023-06-01)

Akinetic mutism in COVID-19-related encephalopathy: A cytokine-mediated maladaptive sickness behavioral response?
by: Umberto Pensato, et al.
Published: (2021-08-01)

Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects
by: Zhaozhao Chen, et al.
Published: (2024-01-01)

Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities
by: Avis Harden, et al.
Published: (2020-08-01)

A Case of Ertapenem Neurotoxicity Resulting in Vocal Tremor and Altered Mentation in a Dialysis Dependent Liver Transplant Patient
by: Ramy M. Hanna, et al.
Published: (2018-12-01)

Secretory co-factors in next-generation cellular therapies for cancer
by: Atsushi Okuma, et al.
Published: (2022-08-01)

CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
by: Joseph W. Fischer, et al.
Published: (2021-06-01)

Rare Delayed Ifosfamide Encephalopathy: A Case Report of Chemotherapeutic Neurotoxicity
by: Ambika Menon, et al.
Published: (2024-02-01)

Encephalopathy in COVID-19 Presenting With Acute Aphasia Mimicking Stroke
by: Umberto Pensato, et al.
Published: (2020-10-01)

CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA
by: Ugo Testa, et al.
Published: (2023-10-01)

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
by: Ana Carolina Caballero, et al.
Published: (2022-07-01)

Editorial: Understanding the Cytokine Release Syndrome: Toward Improving Cancer Immunotherapy
by: Beatriz Martín-Antonio
Published: (2021-03-01)

Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation
by: Susanne H. C. Baumeister, et al.
Published: (2022-03-01)

Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies
by: Christopher Schorr, et al.
Published: (2023-05-01)

Neurological management and work-up of neurotoxicity associated with CAR T cell therapy
by: Nora Möhn, et al.
Published: (2022-01-01)

Liposomal Vincristine as a Bridge Therapy Prior to CAR-T Therapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma?
by: Juskaran Chadha, et al.
Published: (2019-04-01)

Nuclear Risk in the Arctic and Further
by: Kati Juva
Published: (2023-08-01)

Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma
by: M. Kazim Panjwani, et al.
Published: (2020-01-01)

Encephalopathy after Bendamustine Treatment: A Rare Side Effect?
by: Carolina Amado, et al.
Published: (2020-11-01)

Sequential autologous CAR-T and allogeneic CAR-T therapy successfully treats central nervous system involvement relapsed/refractory ALL: a case report and literature review
by: Yifan Liu, et al.
Published: (2024-01-01)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
by: Madiha Iqbal, et al.
Published: (2022-01-01)

An ecotoxicological view on neurotoxicity assessment
by: J. B. Legradi, et al.
Published: (2018-12-01)

P1163: OUTCOMES OF HIGH-RISK LARGE B-CELL LYMPHOMA TREATED WITH STANDARD OF CARE CHEMOIMMUNOTHERAPY: A NON-RANDOMIZED COMPARISON TO FRONTLINE CAR-T CELL THERAPY
by: O. Albanyan, et al.
Published: (2022-06-01)

CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS
by: Ugo Testa, et al.
Published: (2024-01-01)